KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Receivables - Other (2016 - 2017)

Historic Receivables - Other for Pacific Biosciences Of California (PACB) over the last 6 years, with Q3 2017 value amounting to $755000.0.

  • Pacific Biosciences Of California's Receivables - Other changed N/A to $755000.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $755000.0, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2016, which is 5000.0% down from last year.
  • According to the latest figures from Q3 2017, Pacific Biosciences Of California's Receivables - Other is $755000.0.
  • Pacific Biosciences Of California's 5-year Receivables - Other high stood at $10.0 million for Q4 2015, and its period low was $3000.0 during Q4 2013.
  • In the last 4 years, Pacific Biosciences Of California's Receivables - Other had a median value of $2.4 million in 2017 and averaged $3.4 million.
  • In the last 5 years, Pacific Biosciences Of California's Receivables - Other plummeted by 9963.14% in 2013 and then plummeted by 5000.0% in 2016.
  • Pacific Biosciences Of California's Receivables - Other (Quarter) stood at $3000.0 in 2013, then surged by 333233.33% to $10.0 million in 2015, then tumbled by 50.0% to $5.0 million in 2016, then crashed by 84.9% to $755000.0 in 2017.
  • Its last three reported values are $755000.0 in Q3 2017, $755000.0 for Q2 2017, and $2.4 million during Q1 2017.